BIOCORP

Half-year Results as of June 30, 2020

Regulatory News:

BIOCORP (Paris:ALCOR) (FR0012788065 – ALCOR / Eligible PEA PME), a French company specialized in the design, development and manufacture of innovative medical devices, presents its half-year financial results as of June 30, 2020⁽¹⁾.

Éric Dessertenne, CEO of BIOCORP, commented: “The first half of 2020 was exceptional for several reasons. The COVID crisis made the Company fear a slowdown or temporary suspension in the development and manufacture of its products. Up to now, this fear has been lifted thanks to the mobilization of all our teams. To date, the restrictive measures to control the epidemic have had, in the end, only a limited impact on BIOCORP's activities. As for our various development projects under contract or under negotiation, they have not been questioned but have been delayed by several months: the latest payment received from SANOFI as part of our Mallya agreement, initially expected during the first half of the year, was finally received at the end of August. This said, we have a lot to be satisfied with during this unique six-month period: as an innovative company in the field of connected healthcare, BIOCORP has over the period strengthened its intellectual property with the filing of four new patent families and obtained the issuance of five patents in the United States, Russia, China, India and Europe. These new patents are essential as they embody the future expansion of our range of connected products supported by our R&D teams. For example, Mallya technology, a perfect showcase for our expertise, has already begun a life cycle management phase in order to develop its technological platform. Similarly, BIOCORP has initiated research projects in the field of pre-filled syringes with the new Injay product. On the industrial level, BIOCORP signed several particularly structuring partnerships during the first six months of the year: with the American company AMALAGAM RX in the field of diabetes digitization, with the French company THEA for the development of innovative digital solutions in ophthalmology and, of course, with Roche Diabetes Care France for the distribution of Mallya in retail pharmacies. All these contractual achievements will have a positive impact on our revenues throughout next year with the commercial launch of Mallya in several territories. In fact, the decline in our half-year performance in 2020 compared to 2019 is to be considered as transitory. With the team, BIOCORP's management is totally focused on growth. In addition to the proprietary programs you are already familiar with, we are working on other projects, particularly in the field of growth hormone, which could lead to development contracts in the coming months. This will increase our visibility with the pharmaceutical industry by bringing high-performance digital solutions to the shelf, capable of improving the quality of life of patients and create more value for all our shareholders.”